Literature DB >> 26286747

MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Junchao Cai1, JingJing Zhao2, Nu Zhang3, Xiaonan Xu1, Rong Li1, Yang Yi4, Lishan Fang1, Le Zhang1, Mengfeng Li1, Jueheng Wu5, Heng Zhang6.   

Abstract

The molecular mechanism underlying constitutive activation of AKT signaling, which plays essential roles in astrocytoma progression, is not fully characterized. Increasing numbers of studies have reported that microRNAs are involved in the malignant behavior of astrocytoma cells via directly targeting multiple oncogenes or tumor suppressors. Here, we found that microRNA (miR)-542-3p expression was decreased in glioblastoma cell lines and astrocytoma tissues, and reduced levels of miR-542-3p expression correlated with high histopathological grades and poor prognosis of astrocytoma patients. Exogenous miR-542-3p suppressed glioblastoma cell invasion through not only targeting AKT1 itself but also directly down-regulating its two important upstream regulators, namely, integrin-linked kinase and PIK3R1. Notably, overexpressing miR-542-3p decreased AKT1 phosphorylation and directly and indirectly repressed nuclear translocation and transactivation activity of β-catenin to exert its anti-invasive effect. Furthermore, the miR-542-3p expression level negatively correlated with AKT activity as well as levels of integrin-linked kinase and PIK3R1 in human astrocytoma specimens. These findings suggest that miR-542-3p acts as a negative regulator in astrocytoma progression and that miR-542-3p down-regulation contributes to aberrant activation of AKT signaling, leaving open the possibility that miR-542-3p may be a potential therapeutic target for high grade astrocytoma.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  AKT signaling; Akt PKB; astrocytoma; cancer biology; cell invasion; invasiveness; microRNA-542-3p; neurobiology; signal transduction; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26286747      PMCID: PMC4598981          DOI: 10.1074/jbc.M115.649004

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB.

Authors:  Cristina Murga; Muriel Zohar; Hidemi Teramoto; J Silvio Gutkind
Journal:  Oncogene       Date:  2002-01-10       Impact factor: 9.867

2.  Mutations of the PIK3CA gene are rare in human glioblastoma.

Authors:  Wolf Mueller; Masahiro Mizoguchi; Erica Silen; Katrina D'Amore; Catherine L Nutt; David N Louis
Journal:  Acta Neuropathol       Date:  2005-05-28       Impact factor: 17.088

3.  MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2.

Authors:  Ting He; Feifei Qi; Lin Jia; Shan Wang; Nan Song; Lifang Guo; Yan Fu; Yongzhang Luo
Journal:  J Pathol       Date:  2014-02-24       Impact factor: 7.996

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 5.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

6.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Authors:  E C Holland; J Celestino; C Dai; L Schaefer; R E Sawaya; G N Fuller
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

7.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

Authors:  Y Sonoda; T Ozawa; K D Aldape; D F Deen; M S Berger; R O Pieper
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

8.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

9.  Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Authors:  Daniel K Broderick; Chunhui Di; Timothy J Parrett; Yardena R Samuels; Jordan M Cummins; Roger E McLendon; Daniel W Fults; Victor E Velculescu; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas.

Authors:  Huamin Wang; Hua Wang; Wei Zhang; Helen J Huang; Warren S L Liao; Gregory N Fuller
Journal:  Lab Invest       Date:  2004-08       Impact factor: 5.662

View more
  25 in total

1.  Extensive miRNA expression analysis in craniopharyngiomas.

Authors:  Jill Samis; Elio F Vanin; Simone Treiger Sredni; Maria de Fátima de Bonaldo; Fabricio F Costa; Tadanori Tomita; Reema Habiby; Donald Zimmerman; Marcelo B Soares
Journal:  Childs Nerv Syst       Date:  2016-06-07       Impact factor: 1.475

Review 2.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

3.  miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1.

Authors:  Long Yuan; Peng Yuan; Huijuan Yuan; Zhenlei Wang; Zengci Run; Guanglong Chen; Peng Zhao; Benling Xu
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

4.  MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.

Authors:  Xiao Yue; Dechen Cao; FengMing Lan; Qiang Pan; Tingyi Xia; Huiming Yu
Journal:  Neuro Oncol       Date:  2016-03-22       Impact factor: 12.300

Review 5.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

6.  Silencing LncRNA CASC9 inhibits proliferation and invasion of colorectal cancer cells by MiR-542-3p/ILK.

Authors:  Heping Zhang; Jingfang Wang; Taoyuan Yu; Jingmin Wang; Jun Lu; Zongyang Yu
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

Review 7.  MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma.

Authors:  Huda Alfardus; Alan McIntyre; Stuart Smith
Journal:  Biomed Res Int       Date:  2017-07-19       Impact factor: 3.411

8.  MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression.

Authors:  Kristoffer Unterbruner; Frank Matthes; Judith Schilling; Rohit Nalavade; Stephanie Weber; Jennifer Winter; Sybille Krauß
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

9.  MiR542-3p Regulates the Epithelial-Mesenchymal Transition by Directly Targeting BMP7 in NRK52e.

Authors:  Zhicheng Liu; Yuru Zhou; Yue Yuan; Fang Nie; Rui Peng; Qianyin Li; Zhongshi Lyu; Zhaomin Mao; Liyuan Huang; Li Zhou; Yiman Li; Jing Hao; Dongsheng Ni; Qianni Jin; Yaoshui Long; Pan Ju; Wen Yu; Jianing Liu; Yanxia Hu; Qin Zhou
Journal:  Int J Mol Sci       Date:  2015-11-24       Impact factor: 5.923

10.  The Abnormal Expression of MicroRNA-542-3p in Hepatocellular Carcinoma and Its Clinical Significance.

Authors:  Xi Chen; Qi Zhang; Weijie Ma; Tian Lan; Zhenfei Hong; Yufeng Yuan
Journal:  Dis Markers       Date:  2018-02-11       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.